» Articles » PMID: 34177670

Ceremonial Ayahuasca in Amazonian Retreats-Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study

Overview
Specialty Psychiatry
Date 2021 Jun 28
PMID 34177670
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Ayahuasca is a natural psychoactive brew, used in traditional ceremonies in the Amazon basin. Recent research has indicated that ayahuasca is pharmacologically safe and its use may be positively associated with improvements in psychiatric symptoms. The mechanistic effects of ayahuasca are yet to be fully established. In this prospective naturalistic study, 63 self-selected participants took part in ayahuasca ceremonies at a retreat centre in the Peruvian Amazon. Participants undertook the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Self-compassion Scale (SCS), Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM), as well as secondary measures, pre- and post-retreat and at 6-months. Participants also provided saliva samples for pre/post epigenetic analysis. Overall, a statistically significant decrease in BDI-II (13.9 vs. 6.1, < 0.001), STAI (44.4 vs. 34.3 < 0.001) scores, and CORE-OM scores were observed (37.3 vs. 22.3 < 0.001) at post-retreat, as well as a concurrent increase in SCS (3.1 vs. 3.6, < 0.001). Psychometric improvements were sustained, and on some measures values further decreased at 6-month follow-up, suggesting a potential for lasting therapeutic effects. Changes in memory valence were linked to the observed psychometric improvements. Epigenetic findings were equivocal, but indicated that further research in candidate genes, such as sigma non-opioid intracellular receptor 1 (SIGMAR1), is warranted. This data adds to the literature supporting ayahuasca's possible positive impact on mental health when conducted in a ceremonial context. Further investigation into clinical samples, as well as greater analyses into the mechanistic action of ayahuasca is advised.

Citing Articles

A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to....

Hibicke M, Kramer H, Nichols C Psychedelic Med (New Rochelle). 2025; 1(1):54-67.

PMID: 40047006 PMC: 11661400. DOI: 10.1089/psymed.2022.0012.


Examining the epigenetic transmission of risk for chronic pain associated with paternal post-traumatic stress disorder: a focus on veteran populations.

Freeman J, Salberg S, Noel M, Mychasiuk R Transl Psychiatry. 2025; 15(1):42.

PMID: 39910041 PMC: 11799465. DOI: 10.1038/s41398-025-03267-w.


Exploring the Frontier of Cyclic Dipeptides: A Bioinformatics Approach to Potential Therapeutic Applications in Schizophrenia.

Li X, Nong X, Yang J, Li M, Wang Q, Sun M Int J Mol Sci. 2024; 25(21).

PMID: 39518975 PMC: 11546255. DOI: 10.3390/ijms252111421.


Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.

Egger K, Aicher H, Cumming P, Scheidegger M Cell Mol Life Sci. 2024; 81(1):395.

PMID: 39254764 PMC: 11387584. DOI: 10.1007/s00018-024-05353-6.


Epigenetic mechanisms of rapid-acting antidepressants.

Inserra A, Campanale A, Rezai T, Romualdi P, Rubino T Transl Psychiatry. 2024; 14(1):359.

PMID: 39231927 PMC: 11375021. DOI: 10.1038/s41398-024-03055-y.


References
1.
Griffiths R, Richards W, Johnson M, McCann U, Jesse R . Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008; 22(6):621-32. PMC: 3050654. DOI: 10.1177/0269881108094300. View

2.
Hamilton J, Furman D, Chang C, Thomason M, Dennis E, Gotlib I . Default-mode and task-positive network activity in major depressive disorder: implications for adaptive and maladaptive rumination. Biol Psychiatry. 2011; 70(4):327-33. PMC: 3144981. DOI: 10.1016/j.biopsych.2011.02.003. View

3.
Dominguez-Clave E, Soler J, Elices M, Pascual J, Alvarez E, de la Fuente Revenga M . Ayahuasca: Pharmacology, neuroscience and therapeutic potential. Brain Res Bull. 2016; 126(Pt 1):89-101. DOI: 10.1016/j.brainresbull.2016.03.002. View

4.
Loizaga-Velder A, Verres R . Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence--qualitative results. J Psychoactive Drugs. 2014; 46(1):63-72. DOI: 10.1080/02791072.2013.873157. View

5.
Barbosa P, Giglio J, Dalgalarrondo P . Altered states of consciousness and short-term psychological after-effects induced by the first time ritual use of ayahuasca in an urban context in Brazil. J Psychoactive Drugs. 2005; 37(2):193-201. DOI: 10.1080/02791072.2005.10399801. View